We tested whether hypertensive participants in the Genetics of Hypertension Associated Treatment (GenHAT) Study genotyped for MMP9 variants R279Q and R668Q and for MMP12 variants N122S and −82A>G and randomized to either the diuretic chlorthalidone, the calcium channel blocker amlodipine (CCB), or the angiotensin converting enzyme (ACE) inhibitor lisinopril had different outcome rates with regard to six CVD phenotypes. This evidence concerns the gene MMP9 and Hypertension.